Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics pulls Pixuvri filing for non-Hodgkin's lymphoma

Additional time needed to prepare for FDA review

Cell Therapeutics Inc (CTI) has withdrawn its marketing application of non-Hodgkin's lymphoma (NHL) drug candidate Pixuri (pixantrone) in the US after the Food and Drug Administration (FDA) denied additional time to prepare for an advisory committee meeting.

Shares in the company fell on the announcement, which marks the second failure by CTI to guide Pixuvri through the US registration process.

In 2010, the FDA rejected a first application for the drug on the grounds that an additional clinical trial was needed to demonstrate Pixuvri's safety and effectiveness.

If approved, Pixuvri would be used as a last-line treatment for aggressive NHL that no longer responds to other therapies.

The company said it withdrew its New Drug Application (NDA) because it needed additional time to prepare for the review of the Pixuvri NDA by the agency's Oncologic Drugs Advisory Committee (ODAC), scheduled to take place on February 9.

It had requested deferral to a date in late March.

The FDA action date for the NDA was April 24, and CTI said it had no option given the timeframe of withdrawing the application with a view to refilling it later in 2012. The timescale for re-filing and reviewing the dossier looks set to delay the programme by up to 18 months.

In Europe, CTI submitted a marketing application for pixantrone in 2010 and is still going through the registration process.

In the latter half of 2011 the company submitted additional data to the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) and now hopes to hear a verdict on the application sometime later this quarter.

CTI still has no products on the market, and in its third-quarter 2011 results statement indicated that it had about $50m in cash reserves. It has been using up its capital reserves at a rate of about $15m a quarter.

31st January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...